AbbVie Submits Marketing Authorisation Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

Document -

AbbVie Submits Marketing Authorisation Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

• Application supported by four pivotal Phase 3 trials evaluating patients with moderate to severe plaque psoriasis (refs 1-3) • Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit (ref 4) and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing
  • License: All rights reserved
    The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
  • File format: .pdf

Contacts

General Press Enquiries

Press contact 01628 925200

Joanna Jones

Press contact Head of Brand Communications and Patient Relations 07795 590 344

Cheryl Pitcher

Press contact Senior Corporate Communications Manager Internal and Corporate Communications 07500 786 466

Natalie Bennett

Press contact Senior Communications and Patient Relations Manager Immunology - Gastroenterology & Rheumatology 07818 428 074

Sarah Beck

Press contact Senior Brand Communications and Patient Relations Manager, Dermatology Dermatology 07818 428 111

Related content

AbbVie Submits Marketing Authorisation Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

• Application supported by four pivotal Phase 3 trials evaluating patients with moderate to severe plaque psoriasis (refs 1-3) • Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit (ref 4) and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing